{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-246370","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2022-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.900992+00:00","generated_at":"2026-06-23T09:09:37.381329+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Inhibikase Therapeutics presents Phase 1/1b data for IkT-148009 in Parkinson's; Phase 2 ongoing","bullets":["Phase 1/1b of IkT-148009 (88 healthy, 13 PD patients) showed no clinically significant AEs, linear PK, and CNS penetration over 12.5-325 mg daily doses.","In PD mouse models, once-daily oral IkT-148009 preserved >80% SNpc neurons, improved motor function, and reduced pathological alpha-synuclein aggregates.","C-Abl activation is required for PD initiation; IkT-148009 is a selective brain-penetrant c-Abl inhibitor with no organ toxicity seen in toxicology studies.","Phase 2 3-month dosing study (NCT05424276) in mild-to-moderate PD patients has begun to evaluate efficacy and disease modification."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-246370","json":"https://secwatch.observer/filing/0001193125-22-246370.json","markdown":"https://secwatch.observer/filing/0001193125-22-246370.md","text":"https://secwatch.observer/filing/0001193125-22-246370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312522246370/0001193125-22-246370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312522246370/d386213d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:09:37.381329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}